INFORMATION BY CANCER TYPE

Leukemia

Immunotherapy Advancing in Leukemia, Myelodysplastic Syndrome
BY Silas Inman
Checkpoint inhibitors such as Opdivo and Yervoy are showing promise in treating MDS and AML.
The Leukemia & Lymphoma Society Helps Patients Stick with Treatment Regimens through Financial and Other Support
BY Beth Fand Incollingo
By mitigating some of the financial burdens, The Leukemia & Lymphoma Society helps patients better stick to treatment regimens.
Precision Clinical Trial Aims to Find First New Treatment for AML in More than 40 Years
BY Beth Fand Incollingo
The Beat AML trial just launched, and researchers are hoping it will find better treatment for patients with acute myeloid leukemia.
Targeted Power: Improving Prognoses for Patients With Chronic Myeloid Leukemia
BY Tara Haelle

Targeted drugs known as TKIs have improved the prognosis for patients with chronic myeloid leukemia.

Discovering New Patient Subsets Will Help Individualize Acute Lymphoblastic Leukemia Care
BY Gina Columbus
Subsets of patients with acute lymphoblastic leukemia are getting more personalized care.
Some Patients With Chronic Myelogenous Leukemia Delay Treatment Because of Cost
BY Allie Casey
Patients with CML who are insured by Medicare are choosing to delay potentially life-saving treatment due to high costs.
New Agents on Horizon in CLL, Though Advantages Are Not Yet Clear
Novel therapeutic agents have been developed for chronic lymphocytic leukemia (CLL), but their advantage over traditional treatments for this type of cancer have yet to be proved.
Frontline Treatment for Chronic Lymphocytic Leukemia Not One-Size-Fits-All
BY Jason M. Broderick
There are now more personalized treatment options for patients with CLL. 
Blincyto FDA Approved for Pediatric Acute Lymphoblastic Leukemia
BY Jason M. Broderick
The FDA has approved Blincyto (blinatumomab) for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Arzerra Combination FDA Approved in Chronic Lymphocytic Leukemia
BY Silas Inman
Arzerra was approved in combination with fludarabine and cyclophosphamide to treat patients with CLL. 
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Leukemia CURE discussion group.
Search Cancer Drugs & Terms
Treatment
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult acute lymphoblastic leukemia.
Adult Acute Myeloid Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult acute myeloid leukemia.
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of childhood acute lymphoblastic leukemia.
Chronic Lymphocytic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.
Chronic Myelogenous Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic myelogenous leukemia.
Hairy Cell Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of hairy cell leukemia.